Alaunos Therapeutics, Inc. Tangible Asset Impairment Charges
Alaunos Therapeutics, Inc. (TCRT) reported Tangible Asset Impairment Charges of $4.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:TangibleAssetImpairmentCharges · last filed 2025-03-31
- Alaunos Therapeutics, Inc. tangible asset impairment charges for fiscal 2023 was $4.80M.
| Period end | Tangible Asset Impairment Charges | Tangible Asset Impairment Charges as first filed | Tangible Asset Impairment Charges 12 month |
|---|---|---|---|
| 2023-12-31 | $4.80M 10-K · filed 2025-03-31 | ||
| 2023-08-14 | $4.80M 10-K · filed 2024-04-01 | $1.00M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |